Morepen Lab Peer Comparison

NSE: MOREPENLAB | BSE: 500288

₹106.19

₹9.49 (9.81%)

As on 28-Aug-2026IST

Market cap

₹5,820 Cr

Revenue (TTM)

₹1,951 Cr

P/E Ratio

41.4

P/B Ratio

4.5

Div. Yield

0.2 %

Edit

	Morepen Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	5,820	35,825	29,773	16,551	15,559
Revenue (₹ Cr)	1,951	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	140.59	1,018.97	497.77	603.02	270.18
Net Margin (%)	7.13	10.47	20.72	22.63	23.29
RoE (%)	9.61	21.30	28.49	19.61	14.45
Price to Earnings	41.41	35.42	59.81	27.45	56.50
Price-To-Book	4.47	6.83	14.73	4.75	7.50

Income Statement (₹ Cr)

	Morepen Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	1,950.58	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	1,972.67	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	1,766.59	7,739.53	1,608.91	1,753.71	720.01
EBITDA	183.99	1,943.92	762.90	836.69	388.38
Depreciation	35.76	425.10	98.11	78.88	74.78
EBIT	148.24	1,518.82	664.79	757.81	313.60
Interest	17.22	148.45	26.33	5.43	0.26
Other Income	22.09	47.39	30.80	73.83	51.50
Exceptional Items	25.83	-27.85	0.00	-25.66	-3.28
Profit before Tax	178.93	1,389.91	669.26	800.55	361.56
Provision for Tax	38.35	370.94	171.48	197.53	91.39
Profit after Tax	140.59	1,018.97	497.77	603.02	270.18

	Morepen Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	1,246.44	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.05	-7.58	0.00	0.00	2.51
Non-Current Liabilities	198.73	723.57	345.47	142.73	50.51
Current Liabilities	490.30	3,912.24	710.20	508.04	169.08
Total Liabilities	1,778.10	8,121.73	2,179.88	3,753.59	2,034.25

	Morepen Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	623.04	3,392.16	1,290.62	1,321.38	957.22
Current Assets	1,163.62	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	1,778.10	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	79.39	730.70	136.01	0.00	0.38
Net Current Assets	673.31	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	18.32	393.94	8.97	4.82	3.91

	Morepen Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	32.06	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	-321.51	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	299.89	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	10.44	-56.25	44.21	-230.35	-14.24

	Morepen Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	15.48	22.49	23.45	25.50	29.62
ROE (%)	9.61	21.30	28.49	19.61	14.45
ROA (%)	7.57	11.42	19.48	16.31	12.66
EBIT Margin (%)	7.60	15.68	28.03	29.25	28.29
Net Margin (%)	7.13	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Morepen Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	9.48	18.36	78.33	7.93	-6.72
EBIT Growth (%)	29.64	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	50.76	32.39	182.61	21.66	-24.38
EPS Growth (%)	26.81	36.68	277.72	25.42	-21.99
Book Value Growth (%)	36.47	50.94	18.89	20.94	18.74

	Morepen Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	49.56	34.69	59.81	26.58	56.01
Price / Book Value	4.47	6.83	14.73	4.75	7.50
Dividend Yield (%)	0.19	0.19	0.15	0.37	0.51
EV/EBITDA	31.37	18.68	38.82	18.85	38.99
Market Cap (₹ Cr)	2,621.71	20,327.45	15,494.53	13,228.83	17,537.35

	Morepen Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.11	0.05	0.09	0.00	0.00
Short term debt to equity ratio	0.04	0.11	--	--	0.00
Current Ratio	2.37	1.43	2.09	5.21	7.39
Quick Ratio	1.82	0.82	1.37	3.85	5.46
Interest Coverage	11.39	10.36	26.41	148.49	1,386.30

	Morepen Lab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	17.08	26.46	22.82	41.42	41.52
Asset Turnover	1.05	1.09	0.93	0.70	0.52
Receivable days	65.45	87.83	85.17	132.12	132.49
Inventory Days	55.26	78.64	90.97	102.08	68.07
Payable days	107.94	174.97	137.94	133.54	123.94
Cash Conversion Cycle	12.78	-8.50	38.21	100.66	76.63

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.